Dr. Daniel D. Von Hoff Joins RenovoRx’s Advisory Board

Dr. Daniel D. Von Hoff Joins RenovoRx’s Advisory Board

RenovoRx is thrilled to announce that Daniel D. Von Hoff, M.D., F.A.C.P., has joined the company’s Advisory Board. Dr. Von Hoff is a medical oncologist and oncology drug developer who has conducted national clinical trials with more than 200 new agents. He is currently Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona, and CSO for US Oncology Research and for Scottsdale Healthcare’s Clinical Research Institute. He has served on the FDA’s Oncology Advisory Committee as well as on the National Cancer Advisory Board. Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute. Von Hoff became a professor in the departments of medicine and cellular and structural biology at the University of Texas Health Science Center, San Antonio. In 1989, he became the founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and 10 years later he became the Director of the cancer center and Professor of Medicine at the University of Arizona.